NUWE Quote, Financials, Valuation and Earnings

Agenus has a net margin of -63.22% compared to Nuwellis's net margin of -170.88%. Nuwellis's return on equity of -800.59% beat Agenus's return on equity of --.

Nuwellis has a consensus price target of $13.00, signalling upside risk potential of 1357.4%. On the other hand Agenus has an analysts' consensus of $7.00 which suggests that it could grow by 324.24%. Given that Nuwellis has higher upside potential than Agenus, analysts believe Nuwellis is more attractive than Agenus.

Nuwellis has a beta of 0.510, which suggesting that the stock is 49.013% less volatile than S&P 500. In comparison Agenus has a beta of 1.578, suggesting its more volatile than the S&P 500 by 57.761%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Agenus pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $2.3M, which are smaller than Agenus quarterly revenues of $26.8M. Nuwellis's net income of -$1.5M is higher than Agenus's net income of -$45.9M. Notably, Nuwellis's price-to-earnings ratio is -- while Agenus's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 0.16x versus 0.27x for Agenus. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -63.22% compared to Nuwellis's net margin of -49.65%. Nuwellis's return on equity of -800.59% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Nuwellis has a consensus price target of $13.00, signalling upside risk potential of 1357.4%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.56%. Given that Nuwellis has higher upside potential than NovaBay Pharmaceuticals, analysts believe Nuwellis is more attractive than NovaBay Pharmaceuticals.

Nuwellis has a beta of 0.510, which suggesting that the stock is 49.013% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $2.3M, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Nuwellis's net income of -$1.5M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Nuwellis's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 0.16x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -63.22% compared to Nuwellis's net margin of 35.65%. Nuwellis's return on equity of -800.59% beat Protalix BioTherapeutics's return on equity of 8.75%.

Nuwellis has a consensus price target of $13.00, signalling upside risk potential of 1357.4%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 457.69%. Given that Nuwellis has higher upside potential than Protalix BioTherapeutics, analysts believe Nuwellis is more attractive than Protalix BioTherapeutics.

Nuwellis has a beta of 0.510, which suggesting that the stock is 49.013% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $2.3M, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. Nuwellis's net income of -$1.5M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, Nuwellis's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 86.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 0.16x versus 4.04x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -63.22% compared to Nuwellis's net margin of --. Nuwellis's return on equity of -800.59% beat Palatin Technologies's return on equity of --.

Nuwellis has a consensus price target of $13.00, signalling upside risk potential of 1357.4%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Nuwellis, analysts believe Palatin Technologies is more attractive than Nuwellis.

Nuwellis has a beta of 0.510, which suggesting that the stock is 49.013% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $2.3M, which are larger than Palatin Technologies quarterly revenues of --. Nuwellis's net income of -$1.5M is higher than Palatin Technologies's net income of --. Notably, Nuwellis's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 0.16x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.